VCYT vs. VRDN, GH, FLGT, CSTL, CDNA, GTH, BNR, PSNL, RDNT, and FTRE
Should you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Viridian Therapeutics (VRDN), Guardant Health (GH), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), CareDx (CDNA), Genetron (GTH), Burning Rock Biotech (BNR), Personalis (PSNL), RadNet (RDNT), and Fortrea (FTRE).
Viridian Therapeutics (NASDAQ:VRDN) and Veracyte (NASDAQ:VCYT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.
Viridian Therapeutics currently has a consensus price target of $36.60, indicating a potential upside of 156.84%. Veracyte has a consensus price target of $29.00, indicating a potential upside of 46.24%. Given Veracyte's stronger consensus rating and higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than Veracyte.
Veracyte received 384 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 73.02% of users gave Viridian Therapeutics an outperform vote while only 72.88% of users gave Veracyte an outperform vote.
In the previous week, Veracyte had 3 more articles in the media than Viridian Therapeutics. MarketBeat recorded 6 mentions for Veracyte and 3 mentions for Viridian Therapeutics. Veracyte's average media sentiment score of 0.97 beat Viridian Therapeutics' score of 0.11 indicating that Viridian Therapeutics is being referred to more favorably in the media.
Veracyte has a net margin of -20.61% compared to Veracyte's net margin of -75,711.48%. Viridian Therapeutics' return on equity of -2.02% beat Veracyte's return on equity.
Viridian Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.
Veracyte has higher revenue and earnings than Viridian Therapeutics. Veracyte is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Veracyte beats Viridian Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Veracyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Veracyte Competitors List
Related Companies and Tools
